womens health – medical news today

Vaginal itching: Common causes, symptoms, and treatments

Vaginal itching: Common causes, signs, and treatments

For full functionality, it is essential to make it possible for JavaScript. Here are directions ways to make it possible for JavaScript in your web internet browser. We utilize cookies to personalize your browsing experience. By visiting our website, you accept their usage. Find out more. Welcome to a make over for Medical News Today in 2017, part of ongoing improvements and improvements to the way we present our daily health news to you. As always, we welcome your feedback via our contact page. This article provides an overview of common reasons for vaginal itching, in addition to links to more in-depth posts. Many ladies will experience a vaginal yeast infection during their lifetime. Though these aren’t generally severe, yeast infection symptoms can be irritating. Usually, a balance of healthy germs and yeast live in the vagina. The bacteria keep yeast in check, preventing overgrowth. When the vaginal area’s bacteria do not appropriately control the yeast balance, yeast overgrowth can take place. Yeast infections generally happen when something upsets the vaginal area’s bacteria balance. Typical causes consist of: Some health conditions might also make a woman most likely to get a yeast infection. A weakened immune system or unchecked diabetes might i.

See all stories on this topic Contraceptive pill might safeguard versus some cancers for decades

From an analysis of more than 46,000 women, scientists from the University of Aberdeen in the United Kingdom found that ladies who had ever used oral contraceptive tablets were at lower risk of colorectal, ovarian, and endometrial cancers, compared to ladies who had actually never used the pill. Moreover, the study discovered no link between the use of oral contraceptives during reproductive years and increased danger of new cancers in later life. The research study was led by Dr. Lisa Iversen, of the Institute of Applied Health Sciences at Aberdeen, and the findings were recently released in the American Journal of Obstetrics and Gynaecology. According to the Centers for Disease Control and Prevention (CDC), around 16 percent of females in the United States aged in between 15 and 44 years are currently using oral contraceptive pills as an approach of birth control. The “combined tablet” is the most common kind of contraceptive pill utilized. This includes synthetic variations of the hormonal agents estrogen and progesterone. Since naturally happening estrogen and progesterone have been associated with cancer advancement, various studies have examined whether contraceptive pills may play a role in cancer risk. While s.

New medicine to prevent mothers dying in childbirth succeeds in first trial in humans

New medication to prevent mothers passing away in giving birth is successful in very first trial in humans

The Monash University Institute of Pharmaceutical Sciences (MIPS) has announced positive results from a first-in-human study of a new, breathed in type of a medicine that might substantially decrease maternal deaths around the world. The outcomes open the possibility of a structured path to registration, implying that the medicine could be available to mothers rather than would otherwise be possible. Every year, over 300,000 women in low and low-middle income countries pass away throughout pregnancy and childbirth. Postpartum haemorrhage (PPH) is the single largest cause of these deaths. PPH can be avoided by administering a drug called oxytocin, which is suggested by the World Health Organisation and is commonly used in rich nations. However, as an injection, oxytocin needs refrigeration and a skilled doctor to administer it safely. In low and low-middle earnings countries, one or both of these requirements may not be readily available. To resolve this unmet need, researchers at MIPS, in cooperation with GlaxoSmithKline in London, who sponsored the study, have been establishing an inhalable, dry-powder form of oxytocin. Today at the Royal College of Obstetricians and Gynaec …

See all stories on this topic Significant increase in number of females checked for BRCA gene, but numerous high-risk clients are still missing out

For full functionality, it is needed to make it possible for JavaScript. Here are guidelines how to enable JavaScript in your web browser. We use cookies to individualize your surfing experience. By visiting our website, you agree to their usage. Find out more. Discovery of the BRCA genetic anomaly in the mid-90s represented a development in breast and ovarian cancer prevention. About 5-10% of breast cancer cases and 10-18% of ovarian cancer cases can be credited to two BRCA anomalies. Checking for these genetic abnormalities has risen gradually over the previous decade. Previously, primarily ladies with a history of cancer were referred for hereditary screening, but as awareness has grown, more low-risk females are undergoing BRCA screening. A new research study in the American Journal of Preventive Medicine discovered that the percentage of females without a history of cancer who went through BRCA testing increased greatly from 24.3% in 2004 to 61.5% in 2014. “It is estimated that 60%-80% of clients referred for genetic therapy and testing do not fulfill the recommendation requirement based on family history. To optimize the facilities and medical resources allocated for hereditary testing, it is essential to understand the present use …

Osteoporosis drug found safe in long-term trial

Osteoporosis drug found safe in long-term trial

A brand-new research study offers assuring details about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to deal with postmenopausal osteoporosis. Negative occasions that had actually been kept in mind in an essential clinical trial in women age 60 to 90 years of ages treated for 3 years revealed no propensity to increase after a more 3 years of treatment, the research study showed. In addition, women who crossed over from 3 years of placebo to 3 years of denosumab experienced no increase in negative effects compared to females dealt with for the initial 3 years. “All this is consistent with an outstanding safety and tolerability profile for denosumab treatment for osteoporosis,” said Dr. Nelson Watts, lead author of the study results released in Journal of Bone and Mineral Research study. The authors kept in mind that, particularly in older ladies on long-term treatment, many if not all unfavorable occasions could be called “life events” -things that would have taken place whether or not the person was participating in a scientific trial. Short article: Security Observations With Three Years of Denosumab Exposure: Contrast Between Subjects Who Received Denosumab During the Randomized FLEXIBILITY Trial and Subjects Who Crossed Ove …

See all stories on this subject How when to take

a pregnancy test Understanding which kind of pregnancy test is most ideal, and understanding ways to utilize them, assists ensure results are accurate. Whether taken in your home or in a medical professional’s workplace, being notified about the pregnancy test process makes it much easier to understand exactly what the outcomes imply, and what to do next. There are 2 primary types of pregnancy test readily available: urine tests and blood tests. Urine tests can be taken in the house or at the physician’s office. They spot the presence of the pregnancy hormonal agent, human chorionic gonadotropin (hCG). The hCG hormone flows in a lady’s blood as soon as a fertilized egg has connected to the uterus wall. This usually takes place 6 days after fertilization. Inning accordance with the American Pregnancy Association, levels of hCG double every 2 to 3 days, peak by 8 to 11 weeks of pregnancy, and then begin to level off. HCG can generally be discovered by a urine test 12 to 2 Week after conception. Home pregnancy test Home pregnancy tests can be bought in a pharmacy or drugstore. They normally cost less than $20 and are easy to utilize. If used properly, they provide outstanding outcomes. Results are generally noticeable within 3 to 10 minutes or in some cases earlier. A number of different brand names and types …
See all stories on this subject

Common screening tests unsuitable for predicting preterm births

Common screening tests inappropriate for anticipating preterm births

Preterm birth – specified as the birth of a baby prior to reaching the typical 37 weeks of pregnancy – impacts 1 in 10 deliveries in the U.S., according to the Centers for Illness Control and Avoidance (CDC). Worldwide, around 15 million kids are born too soon every year, and preterm births are the number one cause of death among children below 5 years of ages. Health care professionals can predict the probability of a spontaneous birth based on the mother’s previous pregnancies, but forecast for females who have not been pregnant in the past is challenging. However, some previous research studies have recommended that a routine ultrasound assessment of the cervix might assist to expect preterm births. The cervix is the outer, lower part of the uterus that dilates and becomes more narrow throughout labor, and the previous research study has revealed that a shorter cervix might anticipate an early birth. In addition, some scientists have proposed that levels of fetal fibronectin – a protein that “glues” the amniotic sac to the inside of the uterus – might likewise assist to predict premature births. New research study published in JAMA examines the precision of these two approaches. The study was led by Dr. Uma …
See all stories on this subject

The evidence base for Hormone Replacement Therapy (HRT): What can we believe?

The evidence base for Hormonal agent Replacement Treatment (HRT): What can we believe?The ‘truths’that most women and clinicians consider in making the decision to utilize, or not utilize, HRT are often wrong or improperly applied states Teacher Robert D Langer in a paper entitled The evidence base for HRT: what can we believe?, which will be released in the journal of the International Menopause Society, Climacteric. It raises serious concerns about the’realities’that have led ladies and their doctors to believe hormonal agent treatment( frequently called HRT) is risky. The incendiary reports surrounding the early termination of the Women’s Health Initiative(WHI )clinical trial of a particular type of HRT (conjugated horse estrogens with medroxyprogesterone acetate), in 2002, were extremely deceptive. They indicated that the study was stopped because HRT caused breast cancer and cardiac arrest, when in truth the research study was stopped for more subtle factors and there was no statistically considerable damage for either breast cancer or cardiovascular disease. However, that stunning report rapidly resulted in women throughout the world abandoning HRT. Professor Langer, among the principal private investigators in the WHI, explains in his paper the process which led to the distorted reporting of the WHI f.See all stories on this subject

Available drug may protect ovaries and fertility from damage by chemotherapies

Offered drug may safeguard ovaries and fertility from damage by chemotherapies

A drug already utilized to slow tumor development might likewise avoid infertility caused by basic chemotherapies, according to a research study in mice published online in the Proceedings of the National Academy of Sciences. Led by scientists from NYU Langone Medical Center, the research study found that the drug everolimus secures ovaries from cyclophosphamide, a chemotherapy utilized typically against breast cancer, but understood to diminish the supply of egg cells needed to attain pregnancy. Female mice treated with everolimus, in addition to chemotherapy, were discovered to have more than twice as numerous offspring later as mice treated with the chemotherapy alone. Such strong outcomes with a readily available drug, say the research study authors, may speed the procedure of getting permission to evaluate it in premenopausal cancer patients. “Our results argue that everolimus might represent a fertility-sparing drug treatment to match the freezing of eggs and embryos, which are valued methods, but time-consuming, costly, less reliable with age, and not protective of long-term ovarian function,” says very first study author and NYU Langone reproductive endocrinologist Kara Goldman, MD. Following a four-year residency in obstetrics and gyneco …

See all stories on this topic Penn doctor leaders new cosmetic surgery for female genital mutilation

MediLexicon International Ltd, Brighton, UK © & copy; 2004-2017 All rights booked. MNT is the registered trade mark of Healthline Media. This website adheres to the HONcode requirement for trustworthy health information. For complete functionality, it is needed to allow JavaScript. Here are guidelines the best ways to enable JavaScript in your web internet browser. We use cookies to individualize your surfing experience. By visiting our website, you agree to their usage. Find out more. There is new hope for the numerous countless women worldwide who have undergone genital mutilation. A surgeon in Penn Medicine’s Center for Human Appearance has developed a reconstructive treatment that can increase sexual function and, patients’ early experiences suggest, help heal the emotional and mental injuries related to the mutilation. Ivona Percec, MD, PhD, an assistant teacher of Surgery in the division of Cosmetic surgery and associate director of Cosmetic Surgery in the Perelman School of Medication at the University of Pennsylvania, reports on her usage of the technique in three patients in the Aesthetic Surgery Journal. She also calls for higher awareness of this human rights concern in support …